Evaluation of tumor recurrences after radical prostatectomy using 18F-Choline PET/CT and 3T multiparametric MRI without endorectal coil: a single center experience

Felipe Couñago 1*, Manuel Recio 2, Antonio Maldonado 3, Elia del Cerro 1, Ana Aurora Díaz-Gavela 1, Israel J. Thuissard 4, David Sanz-Rosa 4, Francisco José Marcos 1, Karmele Olaciregui 5, María Mateo 6 and Laura Cerezo 7

Abstract

Background: To evaluate and compare the utility of 18F-fluorocholine (18F-CH) PET/CT versus 3-Tesla multiparametric MRI (mpMRI) without endorectal coil to detect tumor recurrences in patients with biochemical relapse following radical prostatectomy (RP). Secondarily, to identify possible prognostic variables associated with mpMRI and 18F-CH PET/CT findings.

Methods: Retrospective study of 38 patients who developed biochemical recurrence after RP between the years 2011 and 2015 at our institution. PET/CT and mpMRI were both performed within 30 days of each other in all patients. The PET/CT was reviewed by a nuclear medicine specialist while the mpMRI was assessed by a radiologist, both of whom were blinded to outcomes.

Results: The median prostate-specific antigen (PSA) value pre-MRI/PET-CT was 0.9 ng/mL (interquartile range 0.4–2.2 ng/mL). There were no differences in the detection rate between 18F-CH PET/CT and mpMRI for local recurrence (LR), lymph node recurrence (LNR) and bone metastases (BM). Separately, mpMRI and 18F-CH PET/CT were positive for recurrence in 55.2% and 52.6% of cases, respectively, and in 65.7% of cases when findings from both modalities were considered together. The detection of LR was better with combined mpMRI and choline PET/CT versus choline PET/CT alone (34.2% vs 18.4%, p = 0.04). Salvage treatment was modified in 22 patients (57.8%) based on the imaging findings. PSA values on the day of biochemical failure were significantly associated with mpMRI positivity (adjusted odds ratio (OR): 30.9; 95% confidence interval (CI): 1.5–635.8). Gleason score > 7 was significantly associated with PET/CT positivity (OR: 13.9; 95% CI: 1.5–125.6). A significant association was found between PSA doubling time (PSADT) (OR: 1.3; 95% CI: 1.0–1.7), T stage (OR: 21.1; 95% CI: 1.6–272.1), and LR.

Conclusions: Multiparametric MRI and 18F-CH PET/CT yield similar detection rates for LR, LNR and pelvic BM. The combination of both imaging techniques provides a better LR detection versus choline PET/CT alone. The initially planned salvage treatment was modified in 57.8% of patients due to imaging findings. In addition to PSA values, Gleason score, T stage, and PSADT may provide valuable data to identify those patients that are most likely to benefit from undergoing both imaging procedures.

Keywords: Prostate cancer, Radical prostatectomy, Biochemical failure, Multiparametric MRI, 18F-Choline PET/CT
Background
After radical prostatectomy (RP), 20–50% of patients with prostate cancer (PCa) will develop a tumor recurrence within ten years [1]. In patients with recurrent disease, accurate identification of the site of recurrence is crucial because the type of salvage treatment administered depends on whether the patient presents pelvic recurrence: local recurrence (LR) with or without pelvic lymph node recurrence (LNR) and/or bone metastases (BM), or extrapelvic distant metastases [2]. Currently, multiparametric magnetic resonance imaging (mpMRI) and 11C or 18F-choline (18F-CH) PET/CT are considered the diagnostic imaging tests of choice in this patient population [2]. However, in recent years prostate-specific membrane antigen (PSMA)-ligand imaging has shown promising results in detecting recurrences after RP, and for this reason use of this approach has become increasingly common [for a Review, see 3].

Multiparametric MRI has proven useful in the detection of LR in the prostate gland, even in patients with low prostate-specific antigen (PSA) levels (<0.5 ng/mL) [4], although few studies have assessed the value of mpMRI to LNR or pelvic bone BM [2, 5]. By contrast, 18F-CH PET/CT has proven effective in detecting LNR and BM after RP primarily in patients with PSA >1 ng/mL or with PSA doubling time (PSADT) < 6 months [6]. The utility of 18F-CH PET/CT to detect LR has received only scant attention [1, 7].

Panebianco et al. compared mpMRI with endorectal coil, dynamic contrast enhanced (DCE), and spectroscopy to 18F-CH PET/CT [7], finding that mpMRI was more reliable at detecting LR. Another study recently compared mpMRI with endorectal coil to 11C-choline PET/CT to detect pelvic recurrences [8], finding that mpMRI was more accurate in detecting LR whereas 11C-PET/CT yielded better results in detecting LNR. Both methods presented similar detection rates for bone metastases. Other studies evaluating the role of PET/CT and mpMRI in PCa staging have found that the sensitivity of mpMRI to nodal metastases is similar to, or slightly lower than, that of choline PET/CT [9–11]. A recent meta-analysis found that mpMRI had a higher sensitivity and a lower specificity than choline PET/CT in the diagnosis of BM [12]. To our knowledge, no studies have been conducted to date to directly compare 3T-mpMRI without endorectal coil with diffusion weighted imaging (DWI) and DCE to 18F-CH PET/CT in the detection of pelvic recurrences after RP.

Given this context, the aim of the present study was to compare 18F-CH PET/CT to 3T mpMRI with a phased-array torso coil to determine their relative capabilities to detect pelvic LR, LNR, and BM after RP and to assess their impact on salvage therapy. Secondarily, we analyzed numerous clinical variables to determine potential predictors of positive findings on the imaging studies.

Methods
Study population
This was a retrospective, observational study of a cohort of 59 patients diagnosed with PCa who underwent 18F-FCH PET/CT at the Nuclear Medicine Department of the Hospital Universitario Quiron in Madrid between November 2011 and July 2015. Of these 59 patients, 21 were excluded from the study due to the following: staging 18F-CH PET/CT performed prior to the initial treatment (n = 5); biochemical failure after radical radiotherapy (n = 10); missing mpMRI (n = 3); lost to follow-up (n = 3). Therefore, all patients who presented a biochemical recurrence (defined as two consecutive elevations of PSA >0.2 ng/mL) after RP and also underwent mpMRI without endorectal coil and 18F-CH PET/CT within a maximum of 30 days of each other were included in the study (n = 38). The PSA values assessed prior to mpMRI and PET/CT imaging were statistically not significantly different. Patients who received salvage RT and/or androgen-deprivation therapy (ADT) after RP (n = 11) were also included. The study was approved by our institution’s ethics committee.

Multiparametric magnetic resonance imaging protocol
The mpMRI protocol has been described in detail elsewhere [3, 13, 14]. Briefly, a 3T MRI was used (Signa HDxt 3.0 T G.E. Healthcare; Milwaukee, WI, USA) with a gradient strength of 33 mT/m and a gradient slew rate of 120 T/m/s. An 8-channel surface coil was used (Torso phased array). Morphological imaging included T1- and T2-weighted sequences and functional studies included DWI and DCE imaging. The apparent diffusion coefficient (ADC) map was calculated while using DWI and b-values of 0 and 1000 s/mm2 were used. DCE imaging was performed with gadolinium contrast. For DCE, a qualitative review was performed and uptake patterns of relapse-suspected lesions were classified as follows: type 1 curve (slow and progressive uptake), type 2 curve (initial uptake followed by a plateau), or type 3 curve (intense initial uptake followed by washout).

18F-choline PET/CT protocol
Patient preparation for PET-CT consisted of 4–6 h of fasting. All patients received an intravenous injection of 18F-fluoromethylcholine (4 MBq/kg) supplied by the Instituto Tecnologico PET (ITP) in Madrid. Whole body scan was started 60–90 min after injection of 18F-CH. Early dynamic images were not obtained. We just acquired late imaging. The whole-body acquisition was performed in the three dimensional mode, using 2 min per bed position from the base of the skull to the mid-thigh (six or seven bed positions). Images were reconstructed with a standard reconstruction ordered-subset expectation maximization iterative algorithm (two iterative steps) and reformatted into transverse, coronal and
sagittal views. Diagnostic CT protocols (oral and intravenous contrasts) were applied. Furosemide was not used in this study. PET-CT scanning was performed using a Biograph 6 True Point HD LSO integrated device (Siemens Healthcare Molecular Imaging; Knoxville, Tennessee, USA) with an intrinsic axial resolution of 4.1 mm FWHM and iterative reconstruction. The CT scan (130–136 keV; 60–90 mAs) was taken in direct proportion to the patient’s weight, followed by a PET scan (performed in the same parameter range) for 3 min per bed (approximately 6–7 min). The PET data were processed with iterative reconstruction and converted into PET images (based on CT) with and without attenuation correction. Acquired images were examined on an LCD monitor as both attenuation-corrected and uncorrected multiplanar PET, CT, and PET/CT fusion cross-sections (maximum intensity projection = MIP), using the eSOFT software (Siemens, USA).

Image analysis
A radiologist and a nuclear physician, both experts in uro-oncology, retrospectively reviewed the mpMRI and 18F-CH PET/CT images. These specialists performed the analysis independently of each other and both were blinded to outcomes. Radiological findings were scored from 1 to 3, as follows: a score of 1 indicated a negative finding (absence of recurrence), 2 was considered indeterminate, and 3 indicated positive findings (presence of recurrence). This same scoring approach was used to assess LR and bone and nodal metastases. All lesions with a score of 1 or 2 were considered negative for the purposes of the present study. The image analyses were performed as follows:

mpMRI
The diffusion sequence and the dynamic contrast-enhanced study were processed in a workstation (Advantage Workstation 4.3; GE Healthcare, Milwaukee, WI, USA). T2 and DWI sequences included the whole pelvis and iliac crests. DCE imaging was performed only in the prostate bed. LR was measured using the T2, DWI and DCE sequences while LNR and BM were assessed with T2 and DWI sequences. There is no validated scoring system to define a recurrence after RP on mpMRI [5]; consequently, we used the following mpMRI criteria for LR: presence of a soft tissue nodule on T2-weighted images in or around the prostatectomy bed in T2-weighted images; the presence of an area or hyperintense nodular lesion on the diffusion map, and a hypointense lesion on the ADC map with low ADC values and a DCE image showing an intense, early enhancement with plateau (type 2 curve) or posterior washing (type 3 curve). LR was positive considered when two or more sequences were abnormal. LNR were considered pathological when the short axis diameter was longer than 8 mm, the MRI signal was heterogeneous, and the contour was irregular. BM was considered pathological when abnormalities were evident on T2 and DWI.

18F-CH PET/CT
18F-CH deposits with higher-than background activity not explained by physiological phenomena were considered positive. Semi-quantitative analysis of the abnormal radiotracer uptake was performed by using the maximum standardized uptake value (SUVmax). This value was obtained automatically.

Salvage treatment
Patients who presented post-RP biochemical recurrence without visible evidence of a tumor on the imaging techniques were treated with rescue RT (70–74 Gy) to the prostate bed. In patients with LR, the dose was increased to 76 Gy. Patients with a pelvic LNR received RT to the pelvic lymph nodes (52.8 Gy at 1.6 Gy/fraction) and the prostatectomy bed (66 Gy at 2 Gy/fraction), together with a simultaneous integrated boost (SIB) to affected lymph nodes (72.6 Gy at 2.2 Gy/fraction). The pelvic BMs were also included within the RT treatment volume with SIB (72.6 Gy at 2.2 Gy/fraction). In patients who had been previously treated with prostate bed RT and later developed pelvic LNR and/or BM, stereotactic fractionated body radiotherapy (SBRT) was prescribed to this localization (excluding the pelvis) as follows: BM: 27–35 Gy in 3 or 5 fractions; LNR: 30–37.5 Gy in 3 or 5 fractions. In oligometastatic (<5 metastases) patients with distant metastases, each lesion was treated with SBRT. ADT was added to the RT prescription at the discretion of the treating physician. However, patients with multiple distant metastases were treated with ADT alone.

Statistical analysis
Quantitative variables are given as medians with interquartile range (IQR) or as a mean ± standard deviation (SD). For qualitative variables, absolute and relative frequencies are given in percentages. The chi-square test was used to analyze qualitative variables. The student’s T test or the Mann–Whitney U Test were used, as appropriate, to analyze significant differences among the quantitative variables.

McNemar’s test was used to analyze differences between mpMRI and 18F-CH PET/CT in detection rates. A per patient analysis was performed. A Venn’s diagram was used to show the distribution of LR and LNR [15].

A univariate/multivariate logistic regression analysis was performed to identify independent variables associated with the imaging findings. The statistical analysis was performed using SPSS, v. 21.0 (IBM Corp; Armonk,
NY; USA), with \( p < 0.05 \) considered significant for all analyses.

**Results**

The clinical characteristics and the variables related to the treatment of the 38 patients included in this study are detailed in Table 1. Treatment before 18F-CH PET/CT and mpMRI imaging consisted of the following: in 27 patients (71.1%), RP alone; in 4 patients (10.5%), RP plus ADT; and in 7 patients (18.4%), RP plus salvage RT. The median time elapsed from RP to mpMRI and 18F-CH PET/CT was 27.5 months [54]. Median age was 62.9 years [7.2]. In 13 cases (34.2%), the tumour stage was pT3. The Gleason score was >7 in 10 (26.3%) patients. Sixteen patients (42.1%) had positive surgical margins. The median PSA value prior to imaging was 0.9 ng/mL (interquartile range 0.4–2.2).

Separately, mpMRI and 18F-CH PET/CT were positive for recurrence in 55.2% (21/38 patients) and 52.6% (20/38 patients) of cases, respectively. When combined findings were considered, 65.7% (25/38 patients) of cases were positive for recurrence (Fig. 1). The combination of MRI and choline PET/CT resulted in a higher detection rate for LR versus choline PET/CT alone (34.2% vs 18.4%, \( p = 0.04 \)). No significant differences were observed between 18F-CH PET/CT imaging and mpMRI imaging in terms of their detection rates for LR, LNR and BM, which were, respectively, as follows: 18.4% vs 31.6% (\( p = 0.12 \)), 31.6% vs 26.3% (\( p = 0.50 \)), and 7.9% vs 10.5% (\( p = 1.00 \)) (Table 2). Distance metastases were detected by 18F-CH PET/CT in 5 patients (3 patients with mediastinal lymph node metastases, 1 with a supraclavicular nodal metastasis, and 1 with retroperitoneal metastases). Overall, the radiological findings of both tests disagreed in 10 cases.

The initially planned salvage treatment was modified in 22 patients (57.8%) due to mpMRI and/or 18F-CH PET/CT findings (Table 3).

**Clinical variables associated with the radiological findings**

The 21 patients with a positive mpMRI had significantly higher PSA values prior to imaging than patients with a negative mpMRI (Table 4). Patients with a positive mpMRI had a significantly higher median PSA at biochemical failure compared to patients with negative mpMRI findings (0.9 [1.2] ng/mL versus 0.4 [0.1] ng/mL, \( p = 0.005 \)). PSA values were significantly associated with a positive mpMRI (odds ratio [OR]: 30.9; 95% confidence interval [CI]: 1.5–635.8) (Table 5).

The 20 patients with a positive 18F-CH PET/CT presented significantly higher PSA values prior to imaging than patients with a negative PET/CT (Table 4). Additionally, the Gleason score and subsequent PET/CT findings were significantly associated: of the 10 patients with a Gleason score >7, nine (90%) had a positive PET/CT; however, of the 28 patients with a Gleason score ≤5, only 11 (39.3%) had a positive PET/CT. Consequently, Gleason score >7 was significantly associated with a positive PET/CT (OR: 13.9; 95% CI: 1.5–125.6) (Table 5).

LR occurred in 13 patients. Additional file 1 shows the distribution of clinical variables in this subgroup. On the multivariate analysis, a significant association was found between PSADT (OR: 1.3; 95% CI: 1.0–1.7), T stage (OR:

---

**Table 1** Clinical, pathologic and treatment related characteristics

| Characteristic | ALL n = 38 |
|---------------|-----------|
| Age, years    | 62.9 ± 7.2|
| Preoperative PSA, ng/mL | 7.4 [9.8] |
| Pathologic T stage | |
| T2            | 25 (65.8) |
| T3            | 13 (34.2) |
| Pathologic N stage | |
| N0            | 16 (42.1) |
| Nx            | 22 (57.9) |
| Pathologic Gleason score | |
| ≤7            | 28 (73.7) |
| >7            | 10 (26.3) |
| Positive surgical margin | |
| Yes           | 16 (42.1) |
| No            | 22 (57.9) |
| Perineural Invasion | |
| Yes           | 17 (44.7) |
| No            | 21 (55.3) |
| Lymphatic vessel invasion | |
| Yes           | 4 (10.5) |
| No            | 34 (89.5) |
| PSA levels, ng/mL | |
| Post radical prostatectomy | 0.1 [0.3] |
| On day of biochemical failure | 0.4 [0.7] |
| On day of choline PET/CT and mpMRI | 0.9 [1.8] |
| Lowest PSA level after surgery | 0.1 [0.3] |
| Treatment before mpMRI/choline PET/CT | |
| Radical prostatectomy only | 27 (71.1) |
| Radical prostatectomy and hormonotherapy | 4 (10.5) |
| Radical prostatectomy and radiotherapy | 7 (18.4) |
| Time from prostatectomy, months | |
| To first PSA recurrence | 10.5 [22.3] |
| To mpMRI/PET/CT | 27.5 [54.0] |
| PSA doubling time, months | 4.5 [8.3] |

Mean ± standard deviation; Median [interquartile range]; n (%)
and the presence of LR (Additional file 2).

A total of 12 patients presented LNR. In patients with a Gleason score > 7, six of 10 patients (60%) developed a LNR versus only six of the 28 patients (21.4%) with a Gleason score ≤ 7, a significant difference (p = 0.04). PSA values (first PSA after surgery, PSA at biochemical failure, and nadir PSA after RP) were all significantly higher in patients who developed LNR. PSADT, the time elapsed from RP to first biochemical recurrence, and time elapsed from surgery to MRI and PET-CT, were all significantly shorter in patients who developed LNR (see Additional file 3). The univariate analysis showed a significant association between Gleason score (OR: 5.5; 95% CI: 1.2–26.0), PSADT (OR: 0.74; 95% CI: 0.56–0.97) and the presence of LNR (see Additional file 4). On the multivariate analysis, no associations were observed between any of the clinical variables and LNR.

**Discussion**

To our knowledge, this is the first study to compare 3T-mpMRI without endorectal coil to 18F-CH PET/CT to determine their relative capacity to detect pelvic tumor recurrences following RP. Although the detection rate of LR, LNR and BM was similar in both imaging techniques, the combination of mpMRI and

|                  | Both tests (%) | PET/CT (%) | mpMRI (%) |
|------------------|--------------|------------|-----------|
| LR               | 13/38 (34.2) | 7/38 (18.4) * | 12/38 (31.6) |
| Pelvic LNR       | 12/38 (31.6) | 12/38 (31.6) | 10/38 (26.3) |
| Pelvic BM        | 4/38 (10.5)  | 3/38 (7.9)  | 4/38 (10.5)  |
| Global           | 25/38 (65.8) | 20/38 (52.6) | 21/38 (55.3) |

**Table 2** Comparison of the detection rate of mpMRI versus 18F-Choline PET/TC versus Both tests in the diagnosis of tumor recurrences in patients with biochemical relapse following radical prostatectomy. The right panel shows a Venn's Diagram of the distribution of the most frequent recurrences of these patients: LR and LNR.

LR local recurrence, LNR lymph node recurrence, BM bone metastases
Statistically significant value, *p < 0.05 vs. Both test are in bold
18F-CH PET/CT was superior to PET/CT alone in the detection of LR.

Few studies have compared mpMRI to choline PET/CT in the context of biochemical relapse after RP. Kitajima et al. retrospectively compared 11C-choline PET/CT to 1.5T and 3T mpMRI with endorectal coil to detect pelvic recurrences after RP in 115 PCa patients [8]. In that study, mpMR imaging with endorectal coil was superior to PET/CT in the detection of LR, but PET/CT was superior for detecting LNR; both were equally excellent for pelvic BM [1]. Panell Bianco et al. compared 3T MRI with endorectal coil to 18F-CH PET/CT in 84 patients with PCa recurrence [7], finding a diagnostic accuracy of MRI for LR higher than that of PET/CT.

In recent years, a new generation of targeted tracers for PET imaging, primarily PSMA, has shown promising results, with a better detection rate than MRI or choline imaging, even in patients with low PSA levels (≤0.5 ng/mL) [3]. However, we are still awaiting the results of validation studies currently in progress [16].

We found that, the tumor detection rate in our patient cohort was high: nearly two-thirds for combined MRI and PET/CT versus approximately half for both MRI and PET/CT alone. In addition, the combination of the imaging techniques versus choline PET/CT alone achieved a significantly higher detection rate for LR. It is worth highlighting the increasing clinical and diagnostic role of the integrated PET/MRI scanner, an advanced technique that combines the anatomical and functional information provided by MRI with the higher specificity of PET [17]. This hybrid PET-MRI system has shown promising results in terms of tumor detection compared to MRI or PET alone [17]. For this reason, the high detection rate for MRI and choline PET/CT allows us to define the site of recurrence, assess for metastatic disease, and personalize salvage therapy. Thus, the use of combined data in our study had an important impact on salvage RT treatment decisions, leading us to change the therapeutic approach in nearly 60% of cases.

Salvage RT is the primary treatment option in patients who suffer a relapse after RP. Although the most common approach is to irradiate the surgical bed (even when there is no radiological or histological evidence of disease), various questions remain unresolved with regard to optimal target volume definition and RT doses [16]. Of the 38 patients in our study, 13 (34.2%) developed LR. In 8 of these patients, we were able to escalate the RT dose to 76 Gy at the recurrence site. This is important because the dose needed to achieve biochemical control can vary depending on whether the recurrence is micro- or macroscopic [18]. Moreover, when the imaging studies show no evidence of recurrence, radiation oncologists define the prostate bed and clinical target volume (CTV) blindly, based on recommendations published in clinical guidelines [19]. However, in some cases, following these guidelines can result in the tumor being excluded from the CTV [20]. Similarly, the decision to irradiate the prostate bed or the whole pelvis will depend on the localization of the recurrence, which can be local or loco-regional.

Although metastatic PCAs has traditionally been treated with ADT alone, the recent increase of metastases-directed therapy in oligometastatic patients, has made it even more important to accurately detect the presence of LNR and BM after RP in order to properly manage these patients [21]. In our study, oligometastatic lesions (bone and/or lymph nodes) were detected outside of the prostate bed in nearly 37% of patients. In these cases, the initial salvage RT plan to the prostate bed would have been completely ineffective. For this reason, the definitive treatment included metastases-directed therapy with RT and ADT. Although it is true that the optimal therapy in patients with nodal or pelvic bone involvement remains unclear, a recent review of studies that assessed surgical and RT treatment of oligometastatic PCAs concluded that, in general, both of these treatment approaches can achieve good outcomes in terms of disease control and increased survival, with only limited toxicity [21].

In terms of the association between clinical variables and the findings of the imaging tests, several points are worth highlighting. Patients with positive MRI and PET/CT findings had PSA values that were significantly
greater than those observed in patients with negative findings on the imaging tests. In fact, although we only found an association between PSA values at the time of biochemical failure and MRI positivity, many studies have reported an association between PSA and choline PET/CT [22]. Thus, after RP, the optimal PSA cut-off level for choline PET/CT analysis seems to be between 1 and 2 ng/mL [23], while for MRI, the corresponding value appears to range from 0.3 to 0.54 ng/mL [5]. In addition to the PSA value, several studies have reported that PSA kinetics (PSADT, PSA velocity) are strong predictors for positive PET and MRI findings, even in patients with low PSA values [4, 5, 23]. We found that PSADT was significantly associated with the type of pelvic recurrence: patients with a higher PSADT had an increased probability of local recurrence. Hernández et al. demonstrated a significantly shorter PSADT in patients with LNR [5].

Table 4 Comparison of the clinical variables of patients with positive and negative mpMRI and 18F-CH PET/CT

|                      | mpMRI |                     | 18F-CH PET/CT |                     |
|----------------------|-------|---------------------|--------------|---------------------|
|                      | Positive | Negative/Uncertain | P value       | Positive | Negative/Uncertain | P value       |
| Age, years           | 63,2 ± 7,2 | 62,5 ± 7,4 | 0,767  | 63,4 ± 7,6 | 62,4 ± 6,8 | 0,703  |
| Preoperative PSA, ng/mL | 7,7 [14,0] | 7,0 [8,4] | 0,453  | 7,4 [9,1] | 7,5 [12,1] | 0,65   |
| Pathologic T stage (%) |        |                     |              |        |                     |              |
| T2                   | 11 (44,0) | 14 (56,0) | 0,086  | 11 (44,0) | 14 (56,0) | 0,182  |
| T3                   | 10 (76,9) | 3 (23,1)  |        | 9 (69,2) | 4 (30,8)  |        |
| Pathologic N stage, n (%) |        |                     |              |        |                     |              |
| N0                   | 9 (56,3)  | 7 (43,8)   | 0,917  | 10 (62,5) | 6 (37,5)  | 0,299  |
| Nx                   | 12 (54,5) | 10 (45,5) |        | 10 (45,5) | 12 (54,5) |        |
| Pathologic Gleason score, n (%) |        |                     |              |        |                     |              |
| ≤ 7                  | 13 (46,4) | 15 (53,6) | 0,136  | 11 (39,3) | 17 (60,7) | 0,009  |
| > 7                  | 8 (80,0)  | 2 (20,0)   |        | 9 (90,0) | 1 (10,0)  |        |
| Positive surgical margin, n (%) |        |                     |              |        |                     |              |
| Yes                  | 8 (50,0)  | 8 (50,0)   | 0,578  | 6 (37,5) | 10 (62,5) | 0,111  |
| No                   | 13 (59,1) | 9 (40,9)   |        | 14 (63,6) | 8 (36,4)  |        |
| Perineural Invasion, n (%) |        |                     |              |        |                     |              |
| Yes                  | 10 (58,8) | 7 (41,2)   | 0,691  | 9 (52,9) | 8 (47,1)  | 0,973  |
| No                   | 11 (52,4) | 10 (47,6) |        | 11 (52,4) | 10 (47,6) |        |
| Lymphatic vessel invasion, n (%) |        |                     |              |        |                     |              |
| Yes                  | 2 (50,0)  | 2 (50,0)   | 1,000  | 2 (50,0) | 2 (50,0)  | 1,000  |
| No                   | 19 (55,9) | 15 (44,1) |        | 18 (52,9) | 16 (47,1) |        |
| PSA levels, ng/mL    |         |                     |              |        |                     |              |
| Post radical prostatectomy | 0,2 [1,4] | 0,0 [0,1] | 0,006  | 0,2 [1,3] | 0,0 [0,1] | 0,007  |
| On day of biochemical failure | 0,9 [1,2] | 0,4 [0,1] | 0,005  | 0,7 [1,1] | 0,4 [0,1] | 0,009  |
| On day of CH PET/CT and mpMRI | 2,0 [1,9] | 0,4 [1,0] | 0,024  | 2,0 [1,7] | 0,4 [0,7] | 0,019  |
| Lowest PSA level after surgery | 0,2 [1,4] | 0,0 [0,1] | 0,012  | 0,2 [1,2] | 0,0 [0,1] | 0,003  |
| Treatment before mpMRI/18F-CH PET, n (%) |        |                     |              |        |                     |              |
| Radical prostatectomy only | 14 (51,9) | 13 (48,1) | 0,508  | 15 (55,6) | 12 (44,4) | 0,572  |
| Prostatectomy and HT or RT | 7 (63,6) | 4 (36,4) |        | 5 (45,5) | 6 (54,5)  |        |
| Time from prostatectomy, months |        |                     |              |        |                     |              |
| To first PSA recurrence | 5,0 [36,0] | 16,0 [18,5] | 0,075  | 5,5 [21,0] | 16,5 [25,0] | 0,079  |
| To mpMRI/PET/CT     | 31,0 [55,5] | 27,0 [44,5] | 0,596  | 10,5 [36,0] | 32,0 [48,0] | 0,187  |
| PSA doubling time, months | 4,0 [9,5] | 5,8 [8,5] | 0,634  | 3,1 [5,3] | 8,5 [9,5]  | 0,135  |

Mean ± standard deviation; Median [interquartile range]
Statistically significant value, p < 0.05 are in bold
positivity [24]. T staging was also significantly associated with LR: patients with extracapsular involvement (T3) had an increased probability of developing LR, a finding that is congruent with the beneficial effect of adjuvant RT in the patient subgroup with extracapsular invasion or seminal vesicle involvement [23]. In short, all of these variables should be taken into account when re-staging patients who develop biochemical recurrence after RP in order to select the most appropriate salvage therapy.

Our study has several limitations. First, this was a retrospective analysis with a small sample size. Second, there was some patient selection bias, as evidenced by the fact that most patients who underwent mpMRI and 18F-CH PET/CT had positive radiological findings. This can be attributed to various factors, as follows: pre-imaging PSA values were relatively high in the entire cohort, the time to biochemical failure was short, and the PSADT values low. All of these clinical characteristics are indicative of highly aggressive disease with a high probability of tumor recurrence that are detectable on both imaging tests. Third, the specific choline PET/CT protocol and the radiotracer used in this study could have influenced the quality of the images and thus their interpretation. However, a recent metanalysis concluded that (11) C-choline and 18F-CH and the different acquisition protocols had no significant impact on the detection rate [25]. Fourth, the MRI and PET images were acquired in separate imaging sessions and this may have affected the detection rate compared to the hybrid PET-MRI system, as mentioned before. Fifth, we did not use endorectal coil and this may have influenced the reliability of the MRI images [26]. Nevertheless, in patients with tumor recurrence after RP, the tumor detection rate using a 3T MRI seems not to be influenced by the type of coil [4]. Lastly, in our study 4 patients received ADT before MRI and PET/CT, which could have a limited uptake on the choline PET/CT and caused morphological changes and alterations in the parameters of the DWI and DCE on the MRI [27, 28]. However, data from our study and others [7] show that this does not directly influence the comparative analysis. In fact, in three of these four patients the recurrence was identified by both imaging techniques.

The strength of the study is the blinded evaluation of all images at the same institution by two different experts (a uro-radiologist and a nuclear medicine specialist). In addition, this is the first study to compare 3T mpMRI without endorectal coil to 18F-CH PET/CT in this context.

**Conclusion**

Multiparametric MRI and 18F-CH PET/CT yield similar detection rates for LR, LNR and pelvic BM. The combination of both imaging techniques provides a better

| Table 5 Univariate analysis of the clinic characteristics associated to the positivity of mpMRI and 18F-CH PET/CT |
|---|---|---|---|---|---|
|  | mpMRI |  | 18F-CH PET/CT |  |
|  | OR (95% CI) | p value | OR (95% CI) | p value |
| Age, years | 1.01 (0.93–1.10) | 0.759 | 1.02 (0.93–1.12) | 0.694 |
| Preoperative PSA, ng/mL | 1.05 (0.95–1.15) | 0.344 | 0.98 (0.89–1.07) | 0.630 |
| Pathologic T stage, T3 | 4.24 (0.94–19.26) | 0.061 | 2.86 (0.69–11.82) | 0.146 |
| Pathologic N stage, Nx | 0.93 (0.26–3.41) | 0.917 | 0.50 (0.13–1.86) | 0.301 |
| Pathologic Gleason score, > 7 | 4.62 (0.83–25.73) | 0.081 | 13.91 (1.54–125.63) | **0.019** |
| Positive surgical margin | 0.69 (0.19–2.53) | 0.578 | 0.34 (0.09–1.30) | 0.116 |
| Perineural Invasion | 1.30 (0.36–4.72) | 0.691 | 1.02 (0.28–3.68) | 0.973 |
| PSA levels, ng/mL |  |  |  |
| Post radical prostatectomy | 20.66 (0.45–964.07) | 0.121 | 2.17 (0.71–6.63) | 0.172 |
| On day of biochemical failure | 30.90 (1.50–635.84) | **0.026** | 2.48 (0.76–8.15) | 0.135 |
| On day of MRI-PET/CT | 1.62 (0.88–2.98) | 0.122 | 1.64 (0.90–2.99) | 0.110 |
| Lowest PSA level after surgery | 16.77 (0.530–531.40) | 0.110 | 2.03 (0.72–5.69) | 0.180 |
| Treatment before mpMRI/choline PET/CT |  |  |  |
| Radical prostatectomy and hormonotherapy or radiotherapy | 1.63 (0.38–6.87) | 0.509 | 0.67 (0.16–2.73) | 0.573 |
| Time from prostatectomy |  |  |  |
| To first PSA recurrence | 0.99 (0.95–1.03) | 0.568 | 0.98 (0.94–1.01) | 0.217 |
| To MRI-PET/CT | 1.00 (0.98–1.02) | 0.807 | 0.99 (0.97–1.01) | 0.203 |
| PSA doubling time, months | 1.02 (0.92–1.12) | 0.772 | 0.94 (0.85–1.05) | 0.271 |

Statistically significant value, p < 0.05 are in bold
LR detection rate after RP versus choline PET/CT alone. The initially planned salvage treatment was modified in 57.8% of patients due to both imaging techniques findings. In addition to PSA values, Gleason score, T stage, and PSADT may provide valuable data to identify those patients that are most likely to benefit from undergoing both imaging procedures.

**Additional files**

| Additional file 1: Comparison of the clinical variables of patients with positive and negative local recurrence. (DOC 69 kb) |
| Additional file 2: Multivariate analysis of the clinical characteristics associated to Local Recurrence. (DOC 31 kb) |
| Additional file 3: Comparison of the clinical variables of patients with positive and negative lymph node recurrence. (DOC 71 kb) |
| Additional file 4: Univariate analysis of the clinic characteristics associated to the Local and Lymph Node recurrence. (DOC 55 kb) |

**Abbreviations**

18F–CH PET/CT: 18-fluorocholine positron emission tomography/computed tomography; ADC: Apparent diffusion coefficient; ADT: Androgen-deprivation therapy; BM: Bone metastases; DCE: Dynamic contrast enhanced; DWI: Diffusion weighted imaging; EAU: European Association of Urology; IQR: Interquartile range; ITP: Instituto Tecnológico PET; LNR: Lymph node recurrence; LR: Local recurrences; mpMRI: Multiparametric magnetic resonance imaging; PSADT: PSA doubling time; RP: Radical prostatectomy; RT: Radiotherapy; SBRT: Stereotactic fractioned body radiotherapy; SD: Standard deviation; SIB: Simultaneous integrated boost; SUVmax: Maximum standardized uptake value

**Acknowledgments**

We wish to thank all the members of the Clinical Radiology, Nuclear Medicine, Urology and Pathology Departments as well as MRI and PET/CT technicians of the Hospital Universitario Quiron Madrid for their invaluable collaboration in this study. We would like to thank Bradley Londres for his assistance in editing and improving the English text.

**Funding**

There was no funding for this work.

**Availability of data and materials**

Data and Materials were recovered from patient record. The presented data is summarized in this paper. The complete datasets can be retrieved from the authors upon formal request from interested readers.

**Authors’ contributions**

FC designed the project, collected and analyzed data, and drafted the manuscript; EDC, AAD, FJM, MR, AM contributed to project design and revised the drafted manuscript; DSR edited tables and figures and revised the manuscript; IT collected and analyzed data; KO revised and helped to translate the manuscript; MM revised the manuscript; LC revised the manuscript. All authors read and approved the final manuscript.

**Competing interests**

The authors declare that they have no competing interests.

**Consent for publication**

Not applicable.

**Ethics approval and consent to participate**

This retrospective study was approved by the institutional review board of the Hospital Universitario Quiron Madrid.

**References**

1. Alfárone A, Panebianco V, Schillaci O, et al. Comparative analysis of multiparametric magnetic resonance imaging and PET/CT in the management of local recurrence after radical prostatectomy for prostate cancer. Crit Rev Oncol Hematol. 2012;84(1):109–21.
2. Schiavina R, Ceci F, Borghesi M, et al. The dilemma of localizing disease relapse after radical treatment for prostate cancer: which is the value of the actual imaging techniques? Curr Radiopharm. 2013;6(2):92–5.
3. Kratochwil C, Afshar-Oromieh A, Kopka K, Haberkorn U, Giesel FL. Current status of prostate-specific membrane antigen targeting in nuclear medicine: clinical translation of chelator containing prostate-specific membrane antigen ligands into diagnostics and therapy for prostate cancer. Semin Nucl Med. 2016;46(5):405–18.
4. Couñago F, del Cerro E, Recio M, et al. Role of 3T multiparametric magnetic resonance imaging in the detection of local recurrent prostate cancer after radical prostatectomy: the radiology oncology point of view. Scand J Urol. 2015;49(5):360–5.
5. Hernandez D, Salas D, Giménez D, et al. Pelvic MRI findings in relapsed prostate cancer after radical prostatectomy. Radiat Oncol. 2015;10:262.
6. Castelucci P, Ceci F, Gazani T, et al. Early biochemical relapse after radical prostatectomy: which prostate cancer patients may benefit from a restaging 11C-Choline PET/CT scan before salvage radiation therapy? J Nucl Med. 2016;55(9):1424–9.
7. Panebianco V, Sciarra A, Di S, et al. Prostate cancer: 1H MRS-DCEMR at 3T versus [(18)F]choline PET/CT in the detection of local prostate cancer recurrence in men with biochemical progression after radical retropubic prostatectomy (RRP). Eur J Radiol. 2012;81(4):700–8.
8. Kitajima K, Murphy RC, Nathan MA, et al. Detection of recurrent prostate cancer after radical prostatectomy: comparison of 11C-choline PET/CT with pelvic multiparametric MR imaging with endorectal coil. J Nucl Med. 2014;55(2):223–32.
9. Budharto T, Joniau S, Leut E, et al. Prospective evaluation of 11C-choline positron emission tomography/computed tomography and diffusion-weighted magnetic resonance imaging for the nodal staging of prostate cancer with a high risk of lymph node metastasis. Eur Urol. 2011;60(1):125–30.
10. Heck MM, Souvatzioglou M, Retz M, et al. Prospective comparison of computed tomography, diffusion-weighted magnetic resonance imaging and [(11)C]choline positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2014;41(6):694–701.
11. Pinauqy JB, De Clermont-Galleran H, Pastier C, et al. Comparative effectiveness of [(18)F]fluorocho-line PET/CT and pelvic MRI with diffusion-weighted imaging for staging in patients with high-risk prostate cancer. Prostate. 2015;75(3):323–31.
12. Sheng G, Deng H, Hu S, Jia Z. Comparison of choline-PET/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a meta-analysis. Skeletal Radiol. 2014;43(11):1503–13.
13. Couñago F, del Cerro E, Díaz-Gavela AA, et al. Tumor staging using 3.0 T multiparametric MRI in prostate cancer after radical prostatectomy. Radiat Oncol. 2015;10:262.
14. Shen G, Deng H, Hu S, Jia Z. Comparison of choline-PET/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a meta-analysis. Skeletal Radiol. 2014;43(11):1503–13.
15. Couñago F, Recio M, del Cerro E, et al. Role of 3 T multiparametric MRI in local staging in prostate cancer and clinical implications for radiation oncology. Clin Transl Oncol. 2014;16(11):993–9.
16. Oliveros JC, Venny. An interactive tool for comparing lists with Venn diagrams. (2007–2015). http://bioinfogp.cnb.csic.es/tools/venny/index.html.
17. Amzalag G, Rager O, Tabouret-Vlaud C, et al. Target definition in salvage radiotherapy for recurrent prostate cancer: the role of advanced molecular imaging. Front Oncol. 2016;6:73.
17. Lindenberg L, Ahlman M, Turkbey B, Mena E, Choyke P. Evaluation of prostate cancer with PET/MRI. J Nucl Med. 2016;57 Suppl 3:111S–6.

18. Drijk P, van Walle L, Decker F, et al. Proposal for magnetic resonance imaging-guided salvage radiotherapy for prostate cancer. Acta Oncol. 2016;1–6. [Epub ahead of print].

19. Poortmans P, Bossi A, Vandeputte K, et al. Guidelines for target volume definition in post-operative radiotherapy for prostate cancer, on behalf of the EORTC Radiation Oncology Group. Radiother Oncol. 2007;84(2):121–7.

20. Wang L, Kudchadker R, Choi S, et al. Local recurrence map to guide target volume delineation after radical prostatectomy. Pract Rad Oncol. 2014;439–46.

21. Van Poppel H, De Meerleer G, Joniau S. Oligometastatic prostate cancer: metastases-directed therapy? Arab J Urol. 2016;14(3):179–82.

22. Mapelli P, Incerti E, Ceci F, Castellucci P, Fanti S, Picchio M. 11C- or 18F-choline PET/CT for imaging evaluation of biochemical recurrence of prostate cancer. J Nucl Med. 2016;57 Suppl 3:43S–8.

23. Mottet N, Bellmunt J, Briers E, et al. Prostate cancer. European Association of Urology (EAU) guidelines. 2016. https://uroweb.org/guideline/prostate-cancer/.

24. Rodado-Marina S, Coronado-Poggio M, Garcia-Vicente AM. Clinical utility of (18)F-fluorocholine positron-emission tomography/computed tomography (PET/CT) in biochemical relapse of prostate cancer after radical treatment: results of a multicentre study. BJU Int. 2015;115(6):874–83.

25. von Eyben FE, Kairemo K. Acquisition with (11)C-choline and (18)F-fluorocholine PET/CT for patients with biochemical recurrence of prostate cancer: systematic review and meta-analysis. Ann Nucl Med. 2016;30(6):385–92.

26. Barentsz OJ, Richenberg J, Clements R, Choyke P, et al. Eur prostate MR guidelines 2012. Eur Radiol. 2012;22:746–57.

27. Hötker AM, Mazaheri Y, Zheng J, et al. Prostate cancer: assessing the effects of androgen-deprivation therapy using quantitative diffusion-weighted and dynamic contrast-enhanced MRI. Eur Radiol. 2015;25(9):2665–72.

28. Evangelista L, Zattoni F, Guttilla A, Basso U, Zattoni F. The effects of androgen deprivation therapy on the 18F-choline uptake in prostate cancer patients undergoing neoadjuvant treatment. Q J Nucl Med Mol Imaging. 2016. [Epub ahead of print].